$CRBP News

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript

Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $30

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript

HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $40 Price Target

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO - Slideshow

Corbus Pharma Reports Updated Data From Phase 1/2 Clinical Study Of CRB-701, Next-Gen Nectin-4 Targeted Antibody Drug Conjugate

Mizuho Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $44

Corbus Pharmaceuticals To Discuss Updated Data For Its Phase 1/2 Trial Of CRB-701 Antibody Drug Candidate To Treat Head And Neck Squamous Cell Carcinoma

Jefferies Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $33

Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $54

Guggenheim Reiterates Buy on Corbus Pharmaceuticals, Maintains $45 Price Target

Corbus Pharmaceuticals Q1 EPS $(1.23) Misses $(1.22) Estimate

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026

Guggenheim Initiates Coverage On Corbus Pharmaceuticals with Buy Rating, Announces Price Target of $45

Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701

Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value

Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity

Corbus Pharmaceuticals Doses Last Participant In Its CANYON-1 Phase 1b Clinical Study Of CRB-913 To Treat Obesity

Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer

Corbus Secures FDA Alignment On CRB-701 Registrational Studies For HNSCC And Cervical Cancer; Updated Phase 1/2 Data Set For ASCO 2026